Unique ID issued by UMIN | UMIN000003091 |
---|---|
Receipt number | R000003752 |
Scientific Title | A pilot study of neoajuvant fluorouracil, epirubicin and cyclophosphamide followed by paclitaxel plus high dose toremifene in women with node positive or high-risk breast cancer. |
Date of disclosure of the study information | 2010/01/26 |
Last modified on | 2019/10/17 08:10:58 |
A pilot study of neoajuvant fluorouracil, epirubicin and cyclophosphamide followed by paclitaxel plus high dose toremifene in women with node positive or high-risk breast cancer.
Neoajuvant FEC followed by paclitaxel plus high dose toremifene in women with node positive or high-risk breast cancer.
A pilot study of neoajuvant fluorouracil, epirubicin and cyclophosphamide followed by paclitaxel plus high dose toremifene in women with node positive or high-risk breast cancer.
Neoajuvant FEC followed by paclitaxel plus high dose toremifene in women with node positive or high-risk breast cancer.
Japan |
Primari breast cancer
Breast surgery |
Malignancy
NO
Study of pathological response in neoajuvant FEC followed by paclitaxel plus high dose toremifene in women with node positive and high-risk breast cancer.
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
pathological response rate.
clinila response rate, adverse events, breast concerving rate.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
high dose toremifene 120mg/body
30 | years-old | <= |
Not applicable |
Female
1.Case signedinformed consent of the patients for the registration
2.Case confirmed by pathological diagnosis
3.Postmenopausal women with breast cancer
4.Node positive, high-risk, stage II breast cancer
5.Case that survival more than 6 months is anticipated
6.Case with PS 0 or 1
7.Case with measurable primary lesions
8.Case with a satisfactory function of a heart/liver/kidney/bone marrow ant to satisfy the next condition
Hb:more than 8g/dl
AST(GOT), ALT(GPT):less than 2.5 times of the normal value upper limit of the institution
WBC:more than 4000/mm3
Plt:more than 100000/mm3
TB:less than 1.5mg/dl
Crea:less than 1.5 times of the normal value upper limit of the institution
1.Case with active other malignancies
2.Case with past history of drug allergy or hypersensitivity
3.Case during pregnancy or lactation
4.Case with adverse myelosuppression
5.Case with infectious disease
6.Case with inflammatory breast cancer
7.Case with metastatic breast cancer
8.Case judged inappropriate by physicians
20
1st name | |
Middle name | |
Last name | Tohru Ohtake |
Fukushima Medical University School of Medicine
Department of Breast Surgery
1 Hikariga-oka, Fukushima
024-547-1259
1st name | |
Middle name | |
Last name | Tatsuko Kawasaki |
Fukushima Medical University School of Medicine
Department of Breast Surgery
1 Hikariga-oka, Fukushima
024-547-1259
Department of Breast Surgery, Fukushima Medical University School of Medicine
Department of Breast Surgery, Fukushima Medical University School of Medicine
Self funding
NO
公立大学法人福島県立医科大学附属病院(福島県)
2010 | Year | 01 | Month | 26 | Day |
Unpublished
Terminated
2009 | Year | 11 | Month | 09 | Day |
2011 | Year | 02 | Month | 22 | Day |
2009 | Year | 11 | Month | 01 | Day |
2012 | Year | 11 | Month | 01 | Day |
2012 | Year | 11 | Month | 01 | Day |
2012 | Year | 11 | Month | 01 | Day |
2012 | Year | 11 | Month | 01 | Day |
2010 | Year | 01 | Month | 26 | Day |
2019 | Year | 10 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003752
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |